Checchi Capital Advisers LLC Sells 5,477 Shares of Pfizer Inc. (NYSE:PFE)

Checchi Capital Advisers LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 7.6% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 66,312 shares of the biopharmaceutical company’s stock after selling 5,477 shares during the quarter. Checchi Capital Advisers LLC’s holdings in Pfizer were worth $2,227,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of PFE. Shine Investment Advisory Services Inc. acquired a new position in shares of Pfizer in the second quarter worth approximately $102,000. D. Scott Neal Inc. lifted its stake in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 504 shares during the period. Franklin Parlapiano Turner & Welch LLC acquired a new position in Pfizer in the first quarter valued at approximately $121,000. Cascade Investment Advisors Inc. lifted its stake in Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 2,200 shares during the period. Finally, Perennial Advisors LLC lifted its stake in Pfizer by 7.9% in the second quarter. Perennial Advisors LLC now owns 5,132 shares of the biopharmaceutical company’s stock valued at $172,000 after buying an additional 376 shares during the period. 69.89% of the stock is owned by institutional investors and hedge funds.

Several brokerages have issued reports on PFE. BMO Capital Markets set a $39.00 price target on Pfizer and gave the company a “buy” rating in a research note on Saturday, November 25th. Vetr raised Pfizer from a “hold” rating to a “buy” rating and set a $38.82 target price on the stock in a research report on Thursday, November 23rd. Jefferies Group set a $39.00 target price on Pfizer and gave the stock a “neutral” rating in a research report on Thursday, November 16th. J P Morgan Chase & Co set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Finally, Goldman Sachs Group set a $36.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Wednesday, November 1st. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $38.66.

Pfizer Inc. (NYSE:PFE) traded down $0.29 during trading hours on Monday, hitting $36.06. The company’s stock had a trading volume of 14,086,837 shares, compared to its average volume of 19,979,410. Pfizer Inc. has a 1 year low of $30.51 and a 1 year high of $36.78. The stock has a market cap of $214,940.00, a PE ratio of 14.54, a P/E/G ratio of 2.57 and a beta of 1.01. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company’s revenue was up .9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.61 EPS. equities analysts expect that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Friday, November 10th were given a dividend of $0.32 per share. The ex-dividend date of this dividend was Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.55%. Pfizer’s dividend payout ratio (DPR) is presently 78.53%.

In other news, insider Sally Susman sold 38,230 shares of Pfizer stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the sale, the insider now directly owns 145,649 shares in the company, valued at approximately $5,097,715. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Alexander R. Mackenzie sold 14,700 shares of Pfizer stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the sale, the insider now owns 117,432 shares in the company, valued at $4,145,349.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 60,280 shares of company stock worth $2,118,988. 0.06% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/04/checchi-capital-advisers-llc-sells-5477-shares-of-pfizer-inc-pfe.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply